These are the 16 Houston startups coming out of UH's RED Labs and Rice's OwlSpark

Best in class

CALI, a wearable physical therapy device for those with vertigo, pitched at the annual event. Photo via getcalibalance.com

For the sixth year, the University of Houston and Rice University have joined forces to give their student entrepreneurs a program to thrive in. RED Labs and OwlSpark, the two universities' accelerator programs, just concluded their seventh class with a presentation from the companies.

Over the past 12 weeks, these 16 startups and their teams of entrepreneurs have worked on their company, developing it, learning how to fundraise for it, and engaging with all sorts of other valuable resources and mentors through the program.

"With an emphasis on experimentation and rapid iteration, we teach disciplined startup strategies that help (students) have an eye for reducing risks and increasing odds," says Kerri Smith, managing director of OwlSpark.

This summer's cohort was hosted out of Station Houston this year, but the two universities have worked together since year two of each of their programs.

"We're very proud of our partnership, because in most other cities, two universities like this would probably be rivals, but we're interested in camaraderie and collaboration in this cohort because they are the future generation of entrepreneurs of Houston," says Kelly McCormick, director of RED Labs. "We really think that this sets an example of how working together produces better results than working against each other."

Adren

While the invention of the EpiPen and other compact anaphylaxis solutions have saved lives, the products are still too large to be constantly available to those who need it. Adren's co-founders created a collapsible autoinjector that can be work as a wristband.

"A functioning drug is only one piece of the puzzle," says Jacob, co-founder of Adren. (He didn't state his last name.) "Medication is only effective if it is accessible to the patient."

The company plans to continue on and patent their product with hopes to enter the marketplace by the next few years.

CookLab

Anyone can find a recipe for anything with the tap of a few keys and the click of of few buttons, but once you add in dietary restrictions, things get tricky. Not to mention the fact that so many healthy recipes aren't even that good for you.

The team at CookLab wants to eliminate this unregulated and confusing corner of the internet. CookLab's first product is a web tool that can determine whether or not a recipe is healthy by the user dropping in the URL. This product is in beta right now.

Down the road, CookLab wants to create a tool for users to be able to submit a recipe they want to make, then have CookLab generate a modified version that follows any dietary needs.

INSU

In a state of emergency where electricity is out, the diabetic population is forced to gamble with their lives when it comes to keeping their insulin insulated and cool.

INSU has a solution. The startup has created a battery operated cooler that can keep insulin from spoiling for 30 days. The battery can be charged by wall outlet or even solar panel.

The company plans to market directly to consumers as well as make strategic partnerships with emergency and health organizations.

auggie

Merchandise lines at concerts are quite possibly the single-most buzzkill of any show. In the age of UberEats and order-ahead apps, auggie sees a solution.

While you're at a show, you can easily order your favorite merch items on the app and choose to have it set aside for pickup that day or even get it mailed to you. The app is live on some downloading stores.

LilySpec

The speculum OB/GYNs use on their patients hasn't changed in 150 years, and, while effective, can be uncomfortable to patients during use. But this doesn't have to be the case.

LilySpec is a speculum designed with the patient in mind. The device is silently deployed, silicon coated for comfort, and adjustable for all women.

The LilySpec team will finish its clinical product this year, and the company's medical partners here in Texas will be able to use it on patients.

Myze

How do you staff a team for an unpredictable job? Emergency rooms face this challenge every single shift. Too many staffers makes the establishment bleed money, while too few causes burnout and even sacrifices quality of care.

Myze is developing a software platform that can use artificial intelligence and predictive analytics to help ERs better staff their teams.

CALI

Those suffering from Vertigo feel like the whole world has turned upside down. CALI is a device that helps those people turn it right back around.

The wearable device allows for users to do balance exercises and claim back control of their own situation.

DASH Innovations

For those relying on a catheter, changing it out requires 150 monthly procedures on average. Each one is another opportunity for infection.

DASH Innovations has created UrinControl, a urethral valve for pediatric patients that can be installed once a month and operated with a remote to control the bladder.

Get-A-Grip

Holding onto a cup is something most everyone takes for granted. For arthritis or muscle damage patients, it's a daunting daily task.

Get-A-Grip is designed to distribute the weight of the cup along the grip and make it easier and more comfortable to hold. While originally designed with these patients in mind, the grip comes in four sizes, with the smallest being perfect for babies grabbing at bottles or small children holding cups.

Everest Security

Preparing for and preventing phishing email-originated data breaches is the new normal for companies, but it's impossible to prevent employees from accidentally opening suspicious emails without thinking.

While there are plenty software protection companies out there, Everest Security couples their software solution with education, a core component for the company.

KickedOC

There are 2 million homes supposedly dedicated for off-campus housing for students, but no one-stop shop to find them. KickedOC is attempting to be that one-stop shop and make it easier for students to find their semester homes.

With listings already up in Houston, the startup hopes to expand its platform to College Station and other Texas college towns next.

Mismo Minds

Creating a creative team can be difficult if you don't have the connections already. Mismo Minds is a platform for artists, videographers, directors, etc. to join forces with others who share their creative vision. It's a social networking tool, project management platform, and job board all rolled into one.

Sports Betz

Typically for sports betting, you have two options: Impersonal bets with large pools or friendly wagers that might not ever pay off. Sports Betz is a platform where the competitive gamblers can casually bet with friends and family — but the money is pulled up front.

CIND

Chivalry is not dead, argues CIND, a new dating app. The app allows for potential matches to introduce themselves with a gift — which range from $2 to $100. Though, the recipient doesn't just walk away with the cash. The money actually goes to the recipient's nonprofit of choice. Only after the donation is made can matches start chatting.

CIND (pronounced like "Cindy") is basically digital donation dating, and everyone wins.

PCATCopycat

The Pharmacy College Admission Test isn't easy — and preparation isn't cheap.

PCATCopycat puts the power back into the hands of students. The online course is only $200 — way cheaper and easier for future pharmacists to navigate.

Second Act

Second Act is the startup that isn't. The non-company started the program with the idea of matching retirees with short-term work at various startups with the thought being that they have a lot of experience and a lot of time on their hands. While a great idea in theory, Second Act hit some walls and the company and idea are no more. The team, however, has a bright future in Houston innovation at other startups and companies.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings